OKYO Pharma (NASDAQ:OKYO) announced on December 11, 2025, new analyses from its Phase 2, placebo-controlled, randomized, double-masked trial of 0.05% urcosimod for the treatment of neuropathic corneal pain (NCP).
The trial, involving 18 patients, provided exploratory data on corneal nerve imaging using in vivo confocal microscopy.
The results showed that patients treated with 0.05% urcosimod experienced median increases in both total nerve fiber count (+2.0 n/0.16 mm², IQR 0.54–3.63) and total nerve fiber length (+2.6 mm/mm², IQR 1.55–5.67; p = 0.057 vs placebo).
In contrast, the placebo group demonstrated median decreases in both nerve count (–1.92 n/0.16 mm², IQR –2.79 to –0.04) and nerve fiber length (–1.63 mm/mm², IQR –3.76 to 0.63).
These results are considered exploratory, with the analysis performed on a small sample size (n = 4 per reported median), but they are described as directionally favorable in terms of supporting corneal nerve structure.
The company plans to continue its investigation into urcosimod as a potential treatment for NCP based on these promising findings.